Rag-17
Gene Mutation
Beijing Tiantan HospitalEarly Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Secretin Johns Hopkins University | Phase 3 | B |
Same molecule, other indications
Rag-17 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →